A detailed history of Davenport & CO LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 430 shares of REGN stock, worth $317,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares
430
Previous 370 16.22%
Holding current value
$317,340
Previous $388,000 16.49%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$1024.09 - $1201.76 $61,445 - $72,105
60 Added 16.22%
430 $452,000
Q2 2024

Aug 06, 2024

SELL
$883.2 - $1071.19 $72,422 - $87,837
-82 Reduced 18.14%
370 $388,000
Q1 2024

May 03, 2024

BUY
$902.69 - $993.35 $70,409 - $77,481
78 Added 20.86%
452 $435,000
Q4 2023

Jan 23, 2024

SELL
$775.18 - $881.7 $2,325 - $2,645
-3 Reduced 0.8%
374 $328,000
Q3 2023

Oct 17, 2023

SELL
$692.45 - $844.37 $1.8 Million - $2.2 Million
-2,601 Reduced 87.34%
377 $310,000
Q2 2023

Jul 20, 2023

SELL
$700.03 - $830.35 $657,328 - $779,698
-939 Reduced 23.97%
2,978 $2.14 Million
Q1 2023

Apr 27, 2023

SELL
$680.49 - $826.97 $690,697 - $839,374
-1,015 Reduced 20.58%
3,917 $3.22 Million
Q4 2022

Jan 20, 2023

SELL
$705.89 - $766.39 $63,530 - $68,975
-90 Reduced 1.79%
4,932 $0
Q3 2022

Oct 11, 2022

SELL
$573.97 - $724.32 $28,124 - $35,491
-49 Reduced 0.97%
5,022 $3.46 Million
Q2 2022

Jul 18, 2022

BUY
$548.35 - $738.84 $15,353 - $20,687
28 Added 0.56%
5,071 $3 Million
Q1 2022

May 02, 2022

BUY
$595.12 - $698.43 $144,614 - $169,718
243 Added 5.06%
5,043 $3.52 Million
Q4 2021

Feb 10, 2022

BUY
$543.48 - $670.97 $1.15 Million - $1.42 Million
2,121 Added 79.17%
4,800 $3.03 Million
Q3 2021

Oct 14, 2021

BUY
$574.03 - $680.96 $1.23 Million - $1.46 Million
2,141 Added 397.96%
2,679 $1.62 Million
Q2 2021

Jul 28, 2021

BUY
$472.8 - $558.54 $254,366 - $300,494
538 New
538 $300,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Davenport & CO LLC Portfolio

Follow Davenport & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.